We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.
| Name | Symbol | Market | Type |
|---|---|---|---|
| Sanofi | NASDAQ:SNY | NASDAQ | Depository Receipt |
| Price Change | % Change | Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| -1.36 | -2.70% | 49.00 | 48.10 | 50.40 | 49.61 | 48.58 | 49.50 | 2,973,970 | 01:00:00 |
From May 2019 to May 2024
By Kim Richters
Sanofi and Translate Bio Inc. are starting the Phase 1/2 clinical trial of their mRNA Covid-19 vaccine candidate, the companies said Friday.
The clinical trial--expected with 415 participants--will assess safety, immune response and reactogenicity, and interim results are expected in the third quarter, Sanofi and Translate said.
Preclinical data for the candidate vaccine MRT5500 had demonstrated high neutralizing antibody levels, they said.
Sanofi and Translate said they are also working on improving the vaccine's temperature stability.
At the same time, pre-clinical studies are continuing to assess MRT5500 and additional mRNA vaccine candidates against SARS-CoV-2 variants, the companies said.
Write to Kim Richters at kim.richters@wsj.com
(END) Dow Jones Newswires
March 12, 2021 01:46 ET (06:46 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
1 Year Sanofi Chart |
1 Month Sanofi Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
